Standard radiotherapy

RADIATION10 trials

Sponsors

Hoffmann-La Roche, SOTIO a.s., Ludwig Institute for Cancer Research, National Institute of Cancerología, Novelwise Pharmaceutical Corporation

Conditions

Bladder CancerCervix CancerColorectal CancerGlioblastomaHead and Neck CancerHead and Neck Squamous Cell CarcinomaHypopharyngeal CarcinomaHypopharynx Cancer

Phase 1

NBM-BMX Administered Orally to Patients with Solid Tumors or Newly Diagnosed Glioblastoma

RecruitingNCT06012695

Novelwise Pharmaceutical CorporationMalignant Neoplasm, Malignant Neoplasm of Brain

Start: 2023-08-11End: 2029-09-30Target: 79Updated: 2024-11-14

Thermoradiotherapy for Locally Advanced Head and Neck Cancer Patients

RecruitingNCT06761937

Erasmus Medical CenterHead and Neck Cancer, Head and Neck Squamous Cell Carcinoma, Hypopharyngeal Carcinoma +2

Start: 2025-05-01End: 2028-10-31Target: 30Updated: 2025-07-25

Phase 2

A Study of Xeloda (Capecitabine) Plus Radiotherapy in Participants With Locally Advanced Rectal Cancer

CompletedNCT00796718

Hoffmann-La RocheColorectal Cancer

Start: 2008-10-31End: 2010-08-31Updated: 2016-08-25

Phase II Study of DCVAC/PCa After Primary Radiotherapy for Patients With High Risk Localized Prostate Cancer

CompletedNCT02107430

SOTIO a.s.Prostate Cancer

Start: 2012-03-31End: 2018-10-31Updated: 2018-11-14

Phase 2 Study of Durvalumab (MEDI4736) in Patients With Glioblastoma

CompletedNCT02336165

Ludwig Institute for Cancer ResearchGlioblastoma

Start: 2015-02-26End: 2021-07-06Updated: 2022-10-12

PACCELIO - FDG-PET Based Small Volume Accelerated Immuno Chemoradiotherapy in Locally Advanced NSCLC

RecruitingNCT06102057

TheraOpLocally Advanced, Stage III Non-small Cell Lung Cancer, Unresectable

Start: 2024-07-01End: 2028-06-30Target: 110Updated: 2025-12-17

Phase 3

Lymphocyte-Sparing And Radio-Immunotherapy in Head and Neck Carcinoma

RecruitingNCT06706401

Centre Leon BerardHypopharynx Cancer, Larynx Cancer, Oropharynx Cancer +1

Start: 2025-02-20End: 2029-01-31Target: 460Updated: 2025-11-18

Unknown Phase

Chemotherapy and Pelvic Hypofractionated Radiation Followed by Surgery Cervical Cancer

National Institute of CancerologíaCervix Cancer

Start: 2017-11-10End: 2025-11-10Target: 100Updated: 2023-11-14

Sparing Parotid Ducts Via MRI Sialography for Reduced Patient Reported Xerostomia

WithdrawnNCT06276946

UNC Lineberger Comprehensive Cancer CenterHead and Neck Cancer, Oropharynx Cancer, Xerostomia

Start: 2025-08-08End: 2029-01-31Updated: 2025-09-05

Evaluation of the Clinical Utility of Online Adaptive Radiotherapy in Bladder Cancer (BLADAPT-GETUG V11)

Not yet recruitingNCT07043543

Institut du Cancer de Montpellier - Val d'AurelleBladder Cancer

Start: 2026-01-15End: 2033-09-30Target: 120Updated: 2025-12-15

Related Papers

Hypofractionated versus standard chemoradiotherapy in the definitive treatment of uterine cervix cancer: interim results of a randomized controlled clinical trial.

2024-01-203 citations

Phase II study to evaluate safety and efficacy of MEDI4736 (durvalumab) + radiotherapy in patients with newly diagnosed unmethylated MGMT glioblastoma (new unmeth GBM).

Journal of Clinical Oncology2019-05-2052 citations

ATIM-38. PHASE 2 STUDY TO EVALUATE THE CLINICAL EFFICACY AND SAFETY OF MEDI4736 (DURVALUMAB, DURVA) + BEVACIZUMAB (BEV) IN BEV-NAÏVE PATIENTS WITH RECURRENT GLIOBLASTOMA (GBM)

Neuro-Oncology2018-11-017 citations

ATIM-12. PHASE 2 STUDY TO EVALUATE THE CLINICAL EFFICACY AND SAFETY OF MEDI4736 (DURVALUMAB [DUR]) IN PATIENTS WITH BEVACIZUMAB (BEV)-REFRACTORY RECURRENT GLIOBLASTOMA (GBM)

Neuro-Oncology2017-11-018 citations

Phase 2 study to evaluate safety and efficacy of MEDI4736 (durvalumab [DUR]) in glioblastoma (GBM) patients: An update.

Journal of Clinical Oncology2017-05-2049 citations

ATIM-04. PHASE 2 STUDY TO EVALUATE THE CLINICAL EFFICACY AND SAFETY OF MEDI4736 (DURVALUMAB [DUR]) IN PATIENTS WITH GLIOBLASTOMA (GBM): RESULTS FOR COHORT B (DUR MONOTHERAPY), BEVACIZUMAB (BEV) NAÏVE PATIENTS WITH RECURRENT GBM

Neuro-Oncology2016-11-0110 citations

Abstract IA20: Phase II study to evaluate the clinical efficacy and safety of MEDI4736 (durvalumab) in patients with glioblastoma (GBM): Results for cohort B (durvalumab monotherapy), bevacizumab-naïve patients with recurrent GBM

Cancer Immunology Research2016-10-31

Phase 2 study to evaluate the clinical efficacy and safety of MEDI4736 (durvalumab) in patients with glioblastoma (GBM).

Journal of Clinical Oncology2016-05-208 citations

Abstract A046: Phase 2 study to evaluate the clinical efficacy and safety of MEDI4736 in patients with glioblastoma (GBM)

Cancer Immunology Research2016-01-01

HCP-12IMPROVING THE EFFICIENCY OF MOLECULAR TESTING FOR EXPEDITED BRAIN TUMOR PATIENT MANAGEMENT AND CLINICAL TRIAL ENROLLMENT

Neuro-Oncology2015-11-01

Phase II study to evaluate the clinical efficacy and safety of MEDI4736 in patients with glioblastoma (GBM).

Journal of Clinical Oncology2015-05-203 citations